Scientists at Korea Research Institute of Chemical Technology and Oncord Bio Inc. have divulged molecular glue degraders targeting protein cereblon (CRBN) and acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer, graft-vs.-host disease, leprosy and inflammatory disorders.